RPG Life Sciences

₹1452 1.5 | 0.1%

WEBSITE BSE:532983 NSE : RPG LIFESCI 10 May, 16:01

Market Cap ₹2401 Cr.

Stock P/E 27.4

P/B 6.4

Current Price ₹1452

Book Value ₹ 226.6

Face Value 8

52W High ₹1740

Dividend Yield 1.1%

52W Low ₹ 749

Edit Ratio

RPG Life Sciences Research see more...

Overview Inc. Year: 2007Industry: Pharmaceuticals & Drugs

RPG Life Sciences Ltd is an India-based organisation, which is engaged in production and advertising and marketing of pharmaceutical merchandise. The Company operates across segments, consisting of Domestic Formulations, International Formulations, Active Pharmaceutical Ingredients (API) and Biotech. It operates via 4 commercial enterprise gadgets, which consist of API, Global Generics, Global Formulation and Biotech. The API product line offers various synthetic APIs inside the general therapeutic class to Europe, Latin America, Asia and the US markets. Global Generics commercial enterprise unit commercializes finished dosage forms in markets, which include North America, European Union and Australia. Global formula product line of the Company manufactures and markets finished dosage formula in domestic and different markets. In Biotechnology space, it gives oncology products thru fermentation route. Its portfolio of merchandise encompass Anastrazole, Exemestane, Lamotrigine Tablet and Azathioprine Tablet.

RPG Life Sciences Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

RPG Life Sciences Quarterly Results

#(Fig in Cr.)	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Net Sales	116	104	129	135	131	118	148	154	154	127
Other Income	1	1	1	1	1	2	2	2	2	2
Total Income	116	105	130	136	131	120	150	155	156	129
Total Expenditure	91	90	101	105	101	103	116	116	116	106
Operating Profit	25	15	29	31	30	18	34	39	40	22
Interest	0	0	0	0	0	0	0	0	0	0
Depreciation	4	4	4	4	4	4	4	4	4	4
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	21	11	25	27	26	14	30	35	36	18
Provision for Tax	6	3	7	7	7	3	8	9	9	5
Profit After Tax	15	8	18	20	19	10	22	26	26	13
Adjustments	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	15	8	18	20	19	10	22	26	26	13
Adjusted Earnings Per Share	8.8	4.5	11	12.1	11.6	6.3	13.4	15.6	16	8

RPG Life Sciences Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	222	236	242	279	294	344	330	376	389	440	513	583
Other Income	2	3	7	2	1	2	1	1	1	3	5	8
Total Income	224	238	249	281	295	346	331	377	390	443	518	590
Total Expenditure	206	224	234	257	265	307	296	316	318	353	409	454
Operating Profit	18	14	15	24	29	39	35	61	72	90	108	135
Interest	7	3	3	2	4	5	5	3	2	1	1	0
Depreciation	10	11	11	10	11	14	15	16	16	16	15	16
Exceptional Income / Expenses	0	64	0	0	0	0	0	-5	0	0	0	0
Profit Before Tax	1	65	1	12	15	20	15	36	54	73	92	119
Provision for Tax	-4	12	0	0	2	7	4	7	14	22	24	31
Profit After Tax	4	53	1	12	12	13	11	29	40	51	68	87
Adjustments	0	0	0	0	9	0	0	0	0	0	0	0
Profit After Adjustments	4	53	1	12	21	13	11	29	40	51	68	87
Adjusted Earnings Per Share	2.7	32.3	0.6	7	7.3	8.1	6.5	17.5	24.2	31.1	40.9	53

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	17%	11%	8%	9%
Operating Profit CAGR	20%	21%	23%	20%
PAT CAGR	33%	33%	39%	33%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	86%	48%	45%	36%
ROE Average	24%	22%	18%	16%
ROCE Average	33%	31%	24%	19%

RPG Life Sciences Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	76	126	125	134	147	155	161	177	216	256	308
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	11	0	0	0	16	10	7	2	1	0	0
Other Non-Current Liabilities	12	6	20	22	-5	-2	3	7	6	8	9
Total Current Liabilities	112	77	67	67	79	121	78	83	80	80	103
Total Liabilities	210	209	212	223	236	284	248	268	303	345	419
Fixed Assets	103	106	105	109	137	131	128	123	113	104	124
Other Non-Current Assets	8	6	22	26	3	10	23	19	14	34	31
Total Current Assets	99	97	86	87	96	143	97	126	176	207	264
Total Assets	210	209	212	223	236	284	248	268	303	345	419

RPG Life Sciences Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	0	0	0	0	0	1	0	0	1	40	57
Cash Flow from Operating Activities	12	-6	-2	33	7	15	46	50	58	65	91
Cash Flow from Investing Activities	-12	59	-10	-15	-30	-16	-19	-11	-8	-35	-106
Cash Flow from Financing Activities	-0	-54	12	-18	23	0	-27	-39	-10	-14	-17
Net Cash Inflow / Outflow	0	0	-0	-0	1	-1	0	0	40	17	-32
Closing Cash & Cash Equivalent	0	0	0	0	1	0	0	1	40	57	25

RPG Life Sciences Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	2.67	32.29	0.6	7.03	7.31	8.13	6.54	17.54	24.19	31.13	40.9
CEPS(Rs)	8.63	38.71	7.47	13.16	14.15	16.8	15.8	27.43	34.15	40.6	50.27
DPS(Rs)	1.2	2	0.8	1.6	2.8	2.4	2.4	4	7.2	9.6	12
Book NAV/Share(Rs)	46.1	76.05	75.68	80.78	88.89	93.58	97.05	106.77	130.88	154.66	186
Core EBITDA Margin(%)	6.81	4.57	3.38	7.68	9.33	9.61	9.34	14.57	16.87	18.18	18.66
EBIT Margin(%)	3.49	27.63	1.49	4.86	5.93	6.51	5.4	9.54	13.2	15.55	16.73
Pre Tax Margin(%)	0.24	26.57	0.4	4	4.74	5.28	4.08	8.87	12.77	15.26	16.53
PAT Margin (%)	1.92	21.84	0.4	4	3.94	3.49	2.93	7.06	9.53	10.74	12.19
Cash Profit Margin (%)	6.22	26.17	4.91	7.5	7.63	7.21	7.09	11.03	13.46	14	14.98
ROA(%)	2.21	25.5	0.47	5.34	5.26	5.17	4.07	11.25	14	15.89	17.71
ROE(%)	5.87	52.87	0.8	8.98	8.62	8.91	6.86	17.21	20.36	21.8	24.01
ROCE(%)	5.99	48.37	2.5	8.97	10.45	12.52	9.81	20.35	27.27	31.46	32.92
Receivable days	63.14	63.9	55.8	48.8	45.37	50.85	53.01	45.38	52.52	34.41	23.17
Inventory Days	46.26	50.1	52.39	46.22	50.44	47.09	46.92	38.91	45.64	53.79	58.57
Payable days	201.98	221.95	147.38	126.79	118.52	137.5	135.21	106.09	138.23	132.94	128.38
PER(x)	23.25	1.86	273.52	31.65	61.53	47.04	37.9	9.72	16	17.98	17.01
Price/Book(x)	1.35	0.79	2.19	2.75	5.06	4.09	2.55	1.6	2.96	3.62	3.74
Dividend Yield(%)	1.94	3.33	0.48	0.72	0.62	0.63	0.97	2.35	1.86	1.72	1.72
EV/Net Sales(x)	0.74	0.48	1.26	1.39	2.68	1.99	1.35	0.78	1.54	1.94	2.13
EV/Core EBITDA(x)	9.21	8.06	20.27	16.06	26.69	17.4	12.64	4.8	8.36	9.48	10.1
Net Sales Growth(%)	14.95	6.28	2.85	15.29	5.13	17.13	-4.01	13.75	3.61	13.11	16.51
EBIT Growth(%)	-7.08	743.57	-94.46	277.27	28.84	37.95	-20.61	96.94	41.21	34.69	24.47
PAT Growth(%)	418.82	1110.88	-98.13	1062	4.04	11.25	-19.63	168.36	37.88	28.7	31.39
EPS Growth(%)	418.83	1110.87	-98.13	1061.98	4.04	11.25	-19.63	168.36	37.88	28.7	31.39
Debt/Equity(x)	0.83	0.12	0.27	0.17	0.3	0.35	0.23	0.07	0.01	0	0
Current Ratio(x)	0.89	1.26	1.28	1.31	1.22	1.18	1.25	1.52	2.21	2.58	2.57
Quick Ratio(x)	0.63	0.77	0.77	0.72	0.64	0.74	0.72	0.96	1.47	1.55	1.64
Interest Cover(x)	1.07	25.99	1.36	5.67	4.99	5.31	4.1	14.21	30.93	52.89	80.72
Total Debt/Mcap(x)	0.61	0.15	0.12	0.06	0.06	0.09	0.09	0.04	0	0	0

RPG Life Sciences Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	72.07	72.07	72.41	72.61	72.61	72.81	72.81	72.81	72.81	72.81
FII	0.2	0.12	0.15	0.08	0.25	0.38	0.34	0.46	0.56	0.89
DII	0.01	0.01	0.01	0.03	0.01	0.11	0.28	1.57	1.78	2.17
Public	27.72	27.8	27.43	27.28	27.12	26.7	26.58	25.16	24.85	24.13
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	1.19	1.19	1.2	1.2	1.2	1.2	1.2	1.2	1.2	1.2
FII	0	0	0	0	0	0.01	0.01	0.01	0.01	0.01
DII	0	0	0	0	0	0	0	0.03	0.03	0.04
Public	0.46	0.46	0.45	0.45	0.45	0.44	0.44	0.42	0.41	0.4
Others	0	0	0	0	0	0	0	0	0	0
Total	1.65	1.65	1.65	1.65	1.65	1.65	1.65	1.65	1.65	1.65

Pros

Company has delivered good profit growth of 39% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 22%
Debtor days have improved from 132.94 to 128.38days.
Company is almost debt free.

Cons

Stock is trading at 6.4 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

RPG Life Sciences News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

RPG Life Sciences

Add Watchlist

RPG Life Sciences Research see more...

Overview Inc. Year: 2007Industry: Pharmaceuticals & Drugs

RPG Life Sciences Share Price

Alert Data

Quarterly Price

Peer Comparison

RPG Life Sciences Quarterly Results

RPG Life Sciences Profit & Loss

Growth Rates

RPG Life Sciences Balance Sheet

RPG Life Sciences Cash Flow

RPG Life Sciences Ratios

RPG Life Sciences Shareholding Pattern

RPG Life Sciences News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!